Truist Initiates Viatris (VTRS) Coverage with Buy Rating, $15 PT

Group 1 - Viatris Inc. is highlighted as a strong investment opportunity under $20, with Truist initiating coverage with a Buy rating and a $15 price target [1][2] - The positive outlook is attributed to a market-leading branded portfolio, a strong position in generics, and a promising pipeline with blockbuster potential [2] - Potential upside includes an earlier-than-expected return to full operations at the Indore manufacturing facility and the possibility of pipeline overdelivery [2] Group 2 - Viatris operates internationally as a healthcare company with four segments: Developed Markets, Greater China, JANZ, and Emerging Markets [3]